Design of a Randomized, Placebo-Controlled, Phase 3 Trial of TofersenInitiated in Clinically Presymptomatic SOD1 Variant Carriers: theATLAS Study (May, 10.1007/s13311-022-01237-4, 2022)

Journal article

Open access

Peer reviewed

Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, Markus Otto and Nita A. Farahany

NEUROTHERAPEUTICS, Vol.19(5)

2022

PMID: 36175782

Files and links (1)

url

https://doi.org/10.1007/s13311-022-01286-9View

Published (Version of record) Open

2 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.52 Neurodegenerative Diseases; 1.52.765 ALS Mechanisms
Web Of Science research areas: Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
ESI research areas: Neuroscience & Behavior

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of TofersenInitiated in Clinically Presymptomatic SOD1 Variant Carriers: theATLAS Study (May, 10.1007/s13311-022-01237-4, 2022)
Creators: Michael Benatar - University of Miami
Joanne Wuu - University of Miami
Peter M. Andersen - Umeå University
Robert C. Bucelli - Washington University in St. Louis
Jinsy A. Andrews - The Neurological Institute
Markus Otto - Martin Luther University Halle-Wittenberg
Nita A. Farahany - Duke University
Publication Details: NEUROTHERAPEUTICS, Vol.19(5)
Publisher: ELSEVIER SCIENCE INC; STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
Academic Unit: Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Neuromuscular Disorders Div
Language: English
Resource Type: Journal article
PMID: 36175782
Record Identifier: 991032830846702976